Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation

Julie L. Gasperini, Amani A. Fawzi, Ani Khondkaryan, Linda Lam, Lawrence P. Chong, Dean Eliott, Alexander C. Walsh, John Hwang, SriniVas R. Sadda

Research output: Contribution to journalArticlepeer-review

129 Scopus citations

Abstract

Aims: To evaluate the effect of switching to bevacizumab or ranibizumab after developing tachyphylaxis during anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularisation (CNV). Methods: The authors reviewed the records of all patients who received both ranibizumab and bevacizumab for treatment of CNV to identify those who developed tachyphylaxis, defined as optical coherence tomography evidence of initial decreased exudation followed by lack of further reduction or an increase in exudation. Signs of exudation included subreitnal fluid (SRF), pigment epithelial detachment (PED) and/or cystoid macular oedema (CMO). Results: 26 eyes were included. 10 were initially treated with bevacizumab and then changed to ranibizumab for persistent SRF, PED and/or CMO. Of these, seven had occult CNV and three had predominantly classic CNV. One eye in the occult CNV group did not respond after being switched to ranibizumab. Six eyes had a positive therapeutic response, after one injection in four eyes, and after two or three injections in one eye each. In the classic group, two responded to ranibizumab and one did not. Sixteen eyes were initially treated with ranibizumab before changing to bevacizumab. Of these, 15 had occult CNV and 1 was predominantly classic. Three of the 16 eyes failed to respond to bevacizumab; 6 improved after one injection and 5 after two injections. Conclusions: Patients with CNV who develop tachyphylaxis to ranibizumab or bevacizumab may respond to another anti-VEGF drug. The majority of cases (81%) in this series demonstrated at least some response after switching therapies.

Original languageEnglish (US)
Pages (from-to)14-20
Number of pages7
JournalBritish Journal of Ophthalmology
Volume96
Issue number1
DOIs
StatePublished - Jan 2012

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation'. Together they form a unique fingerprint.

Cite this